Intel and Teva Pharmaceutical Industries have partnered to monitor patients with Huntingdon's disease using wearable devices. The partnerships aims to analyse mid-stage Huntingdon's disease patients, as this is when the symptoms, such as changes in behaviour and breakdowns in motor skills, are most apparent. In a study published today in Nature Communications, researchers from the University of California, San Diego, found that people who wore Fitbit trackers for three months had significantly lower levels of inflammation than those wearing conventional This platform will analyse the data and grade the individual patient's performance and motor skills.
Intel and Teva Pharmaceutical Industries have partnered to monitor patients with Huntingdon's disease using wearable devices. The partnerships aims to analyse mid-stage Huntingdon's disease patients, as this is when the symptoms, such as changes in behaviour and breakdowns in motor skills, are most apparent. Intel and Teva will ask patients to wear a smartwatch, allowing data to be sent to their cloud platform. This platform will analyse the data and grade the individual patient's performance and motor skills.